Saturday 17 October 2026
Export FBIO’s income statement to Excel — free account
Fortress Biotech, Inc.
FBIO Healthcare Biotechnology
Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024. In the quarter to June 2026, revenue grew 14.0%, EPS fell 116.0%, free cash flow fell 115.4% and total debt fell 35.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.87
0.04
−2.09%
Follow FBIO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 1 | 3 | 2 | 2 | 3 | 3 | 1 | 2 | — |
Altman Z-Score |
(5.47) | (8.99) | (7.79) | (4.48) | (1.87) | (1.05) | (3.02) | (5.89) | (1.57) | (2.07) |
P/S ratio |
1.61 | 0.73 | 0.26 | 0.76 | 2.97 | 5.01 | 3.84 | 1.39 | 9.84 | 6.79 |
Altman Z″-Score (non-manufacturers) |
(12.29) | (21.04) | (17.96) | (9.17) | (2.25) | (0.89) | (5.87) | (12.12) | (2.60) | (4.24) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(8.14) | (3.27) | (0.62) | (1.21) | (5.28) | (11.15) | (5.62) | (1.69) | (8.13) | (6.23) |
Beneish M-Score |
(0.01) | (3.98) | (3.49) | (2.91) | (2.98) | (2.17) | (1.37) | (3.71) | (2.93) | 15.20 |
Dividend Safety Score |
20 | — | — | — | — | — | — | — | — | — |
P/B ratio |
1.64 | 0.00 | 13.77 | 1.15 | 0.90 | 1.16 | 1.94 | 1.89 | 1.41 | 1.35 |
Price to Tangible BV |
2.95 | 0.00 | 0.00 | 2.53 | 0.96 | 1.25 | 2.16 | 2.04 | 1.42 | 2.39 |
EV/Sales |
1.25 | 0.90 | 0.13 | (0.32) | (0.79) | 1.24 | 2.60 | 0.55 | 5.10 | 2.82 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.13 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.20) | (0.65) | (0.09) | 0.14 | 0.46 | (0.68) | (1.00) | (0.15) | (1.08) | (1.01) |
EV/FCF |
(0.75) | (0.44) | (0.07) | 0.12 | 0.41 | (0.62) | (0.90) | (0.14) | (1.03) | (0.82) |
Quick Ratio |
2.20 | 0.95 | 1.13 | 1.62 | 3.26 | 4.99 | 3.32 | 1.63 | 1.95 | 1.77 |
Current Ratio |
2.49 | 1.27 | 1.38 | 1.80 | 3.43 | 5.14 | 3.43 | 2.00 | 2.56 | 1.94 |
Net Debt/EBITDA |
0.43 | (0.01) | 0.15 | 0.43 | 1.45 | 2.01 | 0.44 | 0.03 | 0.80 | 1.01 |
Debt/Assets |
28.25% | 40.19% | 36.33% | 32.65% | 11.95% | 19.85% | 40.38% | 56.39% | 25.41% | 16.53% |
Debt/Equity |
0.84 | (35.26) | 38.35 | 1.92 | 0.21 | 0.34 | 1.26 | 4.03 | 0.52 | 0.34 |
Asset Turnover |
0.38 | 0.37 | 0.37 | 0.22 | 0.19 | 0.16 | 0.20 | 0.14 | 0.08 | 0.11 |
Operating CF/Net income |
34.95 | 1.43 | 1.87 | 1.90 | 1.80 | 1.80 | 2.38 | 1.17 | 1.22 | 0.83 |
Capex/Depreciation |
0.15 | (1.60) | (0.19) | (0.26) | (1.53) | (0.65) | (1.18) | (2.09) | (0.91) | (3.81) |
Interest Coverage |
(6.95) | (8.16) | (9.29) | (14.92) | (12.32) | (6.15) | (9.35) | (11.61) | (11.68) | (17.81) |
| (6.22%) | 177,428.57% | (266.13%) | (68.58%) | (30.60%) | (34.52%) | (86.61%) | (120.00%) | (65.74%) | (65.89%) | |
| (1.14%) | (35.86%) | (29.74%) | (27.39%) | (17.73%) | (16.62%) | (21.75%) | (43.49%) | (32.10%) | (38.08%) | |
ROIC |
(124.61%) | 0.00% | 0.00% | 0.00% | 0.00% | (197.50%) | (255.54%) | (464.85%) | (107.83%) | (210.59%) |
Return on Tangible Assets |
(2.46%) | (251.39%) | (177.81%) | (81.74%) | (24.84%) | (20.56%) | (32.47%) | (124.46%) | (56.26%) | (91.15%) |
Average Days of Receivables |
172.75 | 65.83 | 66.46 | 136.60 | 126.23 | 197.49 | 143.53 | 103.10 | 177.28 | 192.44 |
Research and Development Expense of Revenue |
18.81% | 98.62% | 125.51% | 178.07% | 187.33% | 140.59% | 222.03% | 325.06% | 304.35% | 213.19% |
Selling, General and Administrative Expense of Revenue |
152.38% | 152.11% | 107.65% | 150.05% | 126.24% | 134.14% | 151.76% | 198.54% | 295.14% | 208.24% |
Intangible Assets out of Total Assets |
0.15 | 0.22 | 0.12 | 0.09 | 0.03 | 0.04 | 0.03 | 0.01 | 0.00 | 0.21 |
Share Based Compensation of Revenue |
45.43% | 56.75% | 21.93% | 30.35% | 29.52% | 32.53% | 43.45% | 67.38% | 85.21% | 83.80% |
Graham Net Nets |
0.00 | (1.32) | (2.24) | (0.24) | 0.86 | 0.57 | 0.02 | (0.27) | 0.34 | 0.20 |
Graham Number |
0.00 | 2.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(2.19%) | (154.23%) | (338.45%) | (149.16%) | (31.58%) | (20.18%) | (27.22%) | (263.32%) | (39.54%) | (48.90%) |
Free Cash Flow Yield |
(102.44%) | (278.92%) | (690.76%) | (350.93%) | (65.13%) | (40.33%) | (75.03%) | (289.35%) | (50.38%) | (50.31%) |
Revenue per Share |
2.27 | 2.78 | 10.42 | 12.78 | 12.62 | 9.49 | 10.04 | 9.27 | 6.21 | 6.18 |
Operating CF per Share |
(2.36) | (3.86) | (15.81) | (30.28) | (21.39) | (17.42) | (26.02) | (34.10) | (29.26) | (17.19) |
Capex per Share |
0.04 | (0.72) | (0.26) | (0.49) | (3.00) | (1.49) | (2.57) | (3.23) | (1.44) | (3.94) |
Free Cash Flow per Share |
(2.32) | (4.58) | (16.07) | (30.77) | (24.39) | (18.92) | (28.60) | (37.33) | (30.70) | (21.13) |
Cash per Share |
2.85 | 2.76 | 9.98 | 30.09 | 56.11 | 48.59 | 37.50 | 28.67 | 47.13 | 34.40 |
Shareholders Equity per Share |
2.23 | (0.08) | 0.20 | 8.44 | 41.45 | 41.02 | 19.88 | 6.81 | 43.37 | 31.13 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.23 | (0.08) | 0.20 | 8.44 | 41.45 | 41.02 | 19.88 | 6.81 | 43.37 | 31.13 |
Free Cash Flow |
(64.61) | (95.19) | (130.32) | (182.33) | (132.89) | (90.85) | (104.36) | (108.20) | (85.32) | (56.32) |
Working Capital |
74.10 | 18.97 | 32.11 | 102.72 | 245.42 | 214.39 | 110.64 | 55.59 | 111.74 | 53.07 |
Capital Expenditures |
1.17 | (15.00) | (2.10) | (2.93) | (16.35) | (7.16) | (9.39) | (9.36) | (4.01) | (10.50) |
Net Current Asset Value |
0.48 | (55.50) | (48.92) | (13.84) | 175.84 | 129.74 | 2.36 | (10.04) | 57.73 | 21.87 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.12 | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
(0.02) | 0.26 | 0.02 | 0.04 | 0.24 | 0.16 | 0.26 | 0.35 | 0.23 | 0.64 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.18 | 2.87 | 1.71 | 0.88 | 0.71 | 0.92 | 0.64 | 0.37 | 0.62 | 0.37 |
Cash ROIC |
(33.31%) | (83.81%) | (90.90%) | (56.21%) | (22.95%) | (18.30%) | (34.69%) | (59.34%) | (27.18%) | (27.76%) |
Accounts Receivable Turnover |
3.14 | 4.47 | 3.86 | 2.91 | 2.84 | 2.33 | 3.33 | 3.37 | 2.02 | 3.73 |
Accounts Payable Turnover |
0.37 | 0.30 | 0.27 | 0.33 | 0.47 | 0.36 | 0.30 | 0.20 | 0.14 | 0.05 |
Inventory Turnover |
1.74 | 1.69 | 1.88 | 2.56 | 5.70 | 12.91 | 13.72 | 14.43 | 19.56 | 4.22 |
Average Days of Payables |
822.05 | 1,145.07 | 1,172.85 | 1,155.74 | 1,031.38 | 1,135.19 | 1,228.60 | 2,030.12 | 2,757.36 | 11,224.91 |
Days of Inventory on Hand |
167.88 | 252.28 | 162.72 | 167.93 | 112.19 | 35.11 | 29.70 | 40.40 | 17.06 | 93.79 |
Average Receivables |
20.17 | 12.90 | 21.87 | 26.07 | 24.23 | 19.54 | 11.00 | 7.98 | 8.53 | 4.42 |
Average Payables |
56.31 | 69.53 | 85.50 | 94.05 | 68.02 | 40.42 | 34.76 | 30.85 | 25.96 | 17.37 |
Average Inventory |
12.03 | 12.32 | 12.18 | 12.01 | 5.63 | 1.13 | 0.77 | 0.42 | 0.19 | 0.19 |
Average Assets |
164.89 | 155.87 | 230.91 | 345.40 | 364.96 | 279.92 | 183.71 | 193.47 | 208.34 | 144.67 |
Average Common Equity |
30.27 | (0.03) | 25.80 | 137.95 | 211.44 | 134.76 | 46.14 | 70.12 | 101.73 | 83.62 |
Columns are period end dates